Table 1.
Patient demographics and baseline characteristics
| Characteristic | Value |
|---|---|
| Patients, n | 36 |
| Male, n (%) | 26 (72.2) |
| Age, median (range), yr | 66 (40−83) |
| ECOG PS at screening, n (%) | |
| 0 | 12 (33.3) |
| 1 | 24 (66.7) |
| Disease stage at screening, n (%) | |
| Locally advanced | 8 (22.2) |
| Metastatic | 28 (77.8) |
| Patients with ≥1 prior systemic chemotherapy, n (%) a , b | 5 (13.9) |
| Prior chemotherapy regimens, median (range) | 1 (1−2) |
| Patients with ≥1 prior radiation regimen, n (%) | 3 (8.3) |
a
5‐Fluorouracil (FU) − containing regimen (n = 3), gemcitabine‐containing regimen (n = 4).
b
All five patients received chemotherapy in the neoadjuvant or adjuvant setting. One patient was administered a 5‐FU regimen twice, once each in the neoadjuvant and adjuvant settings. A second patient received two separate gemcitabine regimens in the neoadjuvant setting.
Abbreviation: ECOG PS, Eastern Cooperative Oncology Group performance status.